Photodynamic Therapy During Supportive Periodontal Care: Clinical, Microbiologic, Immunoinflammatory, and Patient-centered Performance in a Split-mouth Randomized Clinical Trial
Overview
Authors
Affiliations
Background: This study investigates the effect of photodynamic therapy (PDT) as monotherapy during supportive periodontal therapy.
Methods: A split-mouth, randomized controlled trial was conducted in patients with chronic periodontitis (N = 22) presenting at least three residual pockets (probing depth [PD] ≥5 mm with bleeding on probing [BOP]). The selected sites randomly received the following: 1) PDT; 2) photosensitizer (PS); or 3) scaling and root planing (SRP). At baseline and 3 and 6 months, clinical, microbiologic (real-time polymerase chain reaction analyses), cytokine pattern (multiplexed bead immunoassay), and patient-centered (regarding morbidity) evaluations were performed.
Results: All therapies promoted similar improvements in clinical parameters throughout the study (P <0.05), except that BOP was not reduced in the PS protocol (P >0.05). Lower levels of Aggregatibacter actinomycetemcomitans were observed in the PDT and SRP protocols at 3 months when compared with the PS protocol (P <0.05). An inferior frequency detection of Porphyromonas gingivalis was observed in the PDT protocol at 3 and 6 months and in the SRP protocol at 6 months from baseline (P <0.05). In addition, PDT protocol presented inferior frequency of P. gingivalis at 3 months when compared with the other therapies (P <0.05). Only patients in the PDT protocol exhibited augmented levels of anti-inflammatory interleukin (IL)-4 and reduced proinflammatory IL-1β and IL-6 throughout the study (P <0.05). Intergroup analyses showed reduced IL-10 and increased interferon-γ and IL-1β levels in the PS protocol when compared with the other therapies during follow-ups (P <0.05). No differences in morbidity were observed between the therapies (P >0.05), although the need for anesthesia was higher in SRP-treated sites (P <0.05).
Conclusion: PDT as an exclusive therapy may be considered a non-invasive alternative for treating residual pockets, offering advantages in the modulation of cytokines.
Ferreira R, Greghi S, Santana A, Zangrando M, Damante C Dent J (Basel). 2025; 13(1).
PMID: 39851609 PMC: 11763426. DOI: 10.3390/dj13010033.
Rodrigues J, Deroide M, Takeshita W, Garcia V, de Molon R, Theodoro L Dent J (Basel). 2025; 13(1).
PMID: 39851597 PMC: 11763938. DOI: 10.3390/dj13010021.
Karrabi M, Baghani Z, Assarzadeh H Lasers Med Sci. 2024; 39(1):301.
PMID: 39709576 DOI: 10.1007/s10103-024-04251-4.
Karrabi M, Baghani Z, Atarbashi-Moghadam F J Indian Soc Periodontol. 2024; 28(2):156-175.
PMID: 39411741 PMC: 11472970. DOI: 10.4103/jisp.jisp_494_23.
Cunha P, Gonsales I, Greghi S, Santana A, Honorio H, Negrato C J Appl Oral Sci. 2024; 32:e20240258.
PMID: 39383343 PMC: 11464078. DOI: 10.1590/1678-7757-2024-0258.